- Home
- FULC vs PROF Comparison
FULC vs PROF Comparison
Compare FULC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- PROF
- Stock Information
- Founded
- FULC 2015
- PROF N/A
- Country
- FULC United States
- PROF Canada
- Employees
- FULC N/A
- PROF N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- FULC Health Care
- PROF Health Care
- Exchange
- FULC Nasdaq
- PROF Nasdaq
- Market Cap
- FULC 210.9M
- PROF 201.2M
- IPO Year
- FULC 2019
- PROF N/A
- Fundamental
- Price
- FULC $2.90
- PROF $7.00
- Analyst Decision
- FULC Hold
- PROF Strong Buy
- Analyst Count
- FULC 8
- PROF 2
- Target Price
- FULC $6.57
- PROF $11.40
- AVG Volume (30 Days)
- FULC 427.3K
- PROF 75.8K
- Earning Date
- FULC 02-25-2025
- PROF 03-06-2025
- Dividend Yield
- FULC N/A
- PROF N/A
- EPS Growth
- FULC N/A
- PROF N/A
- EPS
- FULC N/A
- PROF N/A
- Revenue
- FULC $80,000,000.00
- PROF $10,680,000.00
- Revenue This Year
- FULC N/A
- PROF $56.56
- Revenue Next Year
- FULC N/A
- PROF $151.33
- P/E Ratio
- FULC N/A
- PROF N/A
- Revenue Growth
- FULC 2752.05
- PROF 48.35
- 52 Week Low
- FULC $2.78
- PROF $5.63
- 52 Week High
- FULC $11.85
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- FULC 29.80
- PROF 50.72
- Support Level
- FULC $2.82
- PROF $6.37
- Resistance Level
- FULC $3.09
- PROF $7.41
- Average True Range (ATR)
- FULC 0.30
- PROF 0.47
- MACD
- FULC -0.04
- PROF -0.01
- Stochastic Oscillator
- FULC 10.86
- PROF 45.99
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.